Therefore, the inactivation of GSK3-β may be an important neuroprotective factor in Alzheimer’s disease, since activated GSK3 affects β-amyloid metabolism and tau protein phosphorylation. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.